by lrevers | Apr 15, 2022 | Press Releases
D5Pharma’s groundbreaking new cancer vaccine, MetVax, capitalizes on a precisely defined protein fragment of carcinoembryonic antigen—a well-established mediator of adhesion and tumor implantation— to block metastasis. Read More
by lrevers | Apr 15, 2022 | Press Releases
Our team will be actively seeking partners for our technologies at BIO 2022 in San Diego, 13-16 June. Read About Us
by lrevers | Oct 10, 2021 | Press Releases
Our patented aptamers have demonstrated benefits in animal models of disease. D5Pharma’s lead drug candidate is PEG:CCS13, a PEGylated single-stranded DNA aptamer that is a selective agonist for the inflammatory modulator, CD200R1, a glycoprotein receptor found on the...
